WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) issued the following statement from President and CEO Scott Whitaker as President Trump signed the Opioid Crisis Response Act of 2018 that would address the opioid crisis:
Last week, an article by Barbara Bridgman Perkins, PhD, was published in the Washington Post admonishing the relationships between industry and health care providers to advance radiotherapy treatment. Here is what I submitted in response.
WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) issued the following statement from Matthew Wetzel, vice president and assistant general counsel, regarding this week’s filing of an amicus curiae brief with the Utah Supreme Court in the case of Burningham v. Wright Medical:
ALACHUA, Fla., – RTI Surgical, Inc. (Nasdaq: RTIX), a global surgical implant company, and Paradigm Spine, LLC, a leader in motion preservation and non-fusion spinal implant technology, today announced that they have entered into a definitive agreement whereby RTI will acquire all outstanding equity interest of Paradigm Spine in a cash and stock transaction valued at up to $300 million, consisting of $150 million at closing plus potential future milestone payments. RTI believes this transaction...
The report, from a coalition of stakeholders including leaders from patient groups, academia, government and the private sector, makes several recommendations in an attempt to improve and expand access to advanced radiotherapy services in the UK.
SAN DIEGO, CA ., Aug. 23, 2018 - Dthera™ Sciences, the leading digital therapeutic company focusing on the elderly and individuals with neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to the Company's development-stage product, DTHR-ALZ.
If your health care is covered by Medicare, like more than 55 million of your fellow Americans, where you live partly determines what Medicare will pay for. The process for deciding what items and services are covered from region to region needs reform.
SAN ANTONIO, TX., May 23, 2018 - CeloNova BioSciences, Inc. (CeloNova), a global medical device company that offers a family of innovative products based upon its proprietary Polyzene™-F nanocoating technology, today announced 1-year clinical trial results from the eCOBRA post-market study of the company's COBRA PzF™ NanoCoated Coronary Stent (NCS) System. The clinical trial results demonstrated 4.3% target lesion revascularization, 0.3% late stent thrombosis and 8.6% major adverse...